Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Fingolimod Hydrochloride

Criteria

Inclusion Criteria:

• 18-65 years of age, must have relapsing MS

Exclusion Criteria:

• Patients with a type of MS that is not relapsing

• Patients with history of chronic immune disease

• Patients with a history of certain cancers

• Diabetic patients with certain eye disorders

• Patients who are on certain immunosuppressive medications or heart medications

• Patients with certain heart conditions

• Patients with certain lung conditions

Other protocol-defined inclusion/exclusion criteria may apply.